The Alzheimer's disease-related protein, tau, aggregates into neurofibrillary tangles when it is hyperphosphorylated. The amino acid sequence included in the third repeat (R3) of the microtubule-binding region is suspected to be the main factor for tau aggregation. Here, we synthesized a 31-residue oligopeptide, corresponding to the R3 region, and characterized its aggregation propensity under various conditions. This peptide aggregated even in the absence of an aggregation-inducing molecule at a low salt concentration, while it did not form any aggregates at a high salt concentration. This suggests that hydrophilic interactions are the main cause of aggregation. We then investigated the function of FK506-binding protein (FKBP) 12, which is known to accumulate in neurofibrillary tangles in vivo, on aggregation of the R3 peptide and found that FKBP12 completely prevented the peptide from aggregating at a concentration ratio of 1 : 4 (peptide:FKBP12). FKBP12 also restored the oligomer of the peptide to its monomeric status. Mutational studies on the catalytic center of FKBP12 indicated that peptidyl-prolyl isomerase activity of FKBP12 was essential for prevention of aggregation. Assuming that the propensity of aggregation of the peptide is different in each cis-/transisomer, we propose that the aggregation behavior of the R3 peptide can be theoretically described with a simple kinetic scheme, in which only the cis-isomer can aggregate and FKBP12 catalyzes isomerization of the peptide in both the monomeric and aggregative states.
Introduction
The tau protein is essential for assembly and stability of microtubule, which mainly consists of two types of tubulin (Weingarten et al., 1975; Lindwall and Cole, 1984) . Hyperphosphorylation of tau abolishes its ability to bind to tubulin and promote microtubule assembly (Bramblett et al., 1993; Yoshida and Ihara, 1993) . When it is released from tubulin, phosphorylated tau protein aggregates into neurofibrillary tangles (NFTs), which are the neuropathological hallmarks of Alzheimer's disease (AD) (Goedert et al., 1988 ; Morishima-Kawashima et al., 1995). Perez et al. (2001) showed that the microtubule-binding domain (MBD) of tau protein is involved in the core of NFT (Fig. 1) . The ability to aggregate, however, was impaired in a variant of 3-repeat isoforms of tau protein, which lacked six residues Val306-Gln307-Ile308-Val309-Tyr310-Lys311, in the third region (R3), even though it was hyperphosphorylated. This suggests that the main factor for aggregation of tau protein is included in R3 (Perez et al., 2007) .
Dissection analysis was carried out for the MBD. Peptides corresponding to each of the four regions of the MBD (R1, R2, R3 and R4) and various combinations of these (R1-R3, R2-R3, R3 -R4, R1-R2 -R3, R1-R2 -R3-R4 etc.) were chemically synthesized, and their aggregations were investigated by fluorescence-coupled circular dichroism and dynamic light scattering (Mizushima et al., 2006; Zhou et al., 2006; Sugino et al., 2009) . Only the peptides including R2 and/or R3 formed filaments in the presence of heparin, although their aggregation processes differed from each other.
A study in 1997 found that a peptidyl-prolyl isomerase (PPIase), Pin1, which specifically isomerized phosphorylated serine or threonine preceding a proline (pSer/Thr-Pro), restored the function of Alzheimer-associated phosphorylated tau protein (Yaffe, 1997; Lu et al., 1999) . Pin1 catalyzed prolyl isomerization of specific pSer/Thr-Pro motifs in tau protein to facilitate their dephosphorylation by a Pro-directed phosphatase, PP2A, which was conformation-specific and effectively dephosphorylated only the trans-pSer/Thr-Pro isomer (Zhou et al., 2000) . A high aggregation-prone (cis) isomer was converted to a low aggregation-prone (trans) isomer by PPIase activity of Pin1 (Nakamura et al., 2012) . As a result, the dephosphorylated tau protein regained ability for assembly and stability of microtubule (Zhou et al., 2000) . Phosphorylated sites were mapped on the sequences of various isoforms of tau protein (Brion et al., 1993; Goedert et al., 1993; Kopke et al., 1993; Morishima-Kawashima et al., 1995; Liu et al., 2007) . Pin1 worked on several specific sites of at least 30 phosphorylated sites (Lu et al., 1999; Hamdane et al., 2002; Smet et al., 2004; Hamdane et al., 2006; Landrieu et al., 2010; Ogawa et al., 2010) . Phosphorylated Thr231-Pro232 was identified as the major target of Pin1 (Lu et al., 1999; Zhou et al., 2000; Nakamura et al., 2012) . No pSer/Thr-Pro motif, however, exists on the MBD, indicating that Pin1 does not directly affect the highest aggregation region of tau protein.
Recently, FK506-binding protein (FKBP) 12, FKBP51 and FKBP52 were found to bind to tau (Cao and Konsolaki, 2011) . FKBPs are PPIases bound to FK506 and rapamycin (Siekierka et al., 1989) , and they generally show much higher PPIase activity on Xaa-Pro (Xaa; a standard amino acid residue) motifs than on pSer/Thr-Pro motif (Yaffe, 1997) . Both of the large FKBPs, FKBP51 (51 kDa) and FKBP52 (52 kDa), are involved in tau turnover (Chambraud et al., 2010; Jinwal et al., 2010) . Although FKBP51 and FKBP52 have very similar structure and both are mostly ubiquitously expressed, these proteins exert opposite effects on tau protein. FKBP51 promotes the association of tau protein with Hsp90, leading to dephosphorylation and proper recycling of tau protein (Jinwal et al., 2010) , whereas FKBP52 binds directly and specifically to tau protein, preventing tau protein from binding to tubulin (Chambraud et al., 2010) . On the other hand, the smaller FKBP12 (12 kDa) co-localized with NFT in AD brains, suggesting that FKBP12 interacted with abnormal forms of tau protein (Harding et al., 1989; Sugata et al., 2009) . It is possible that FKBP12 interacts with the MBD of tau protein because the MBD contains eight Xaa-Pro motifs. Assuming each cis-/ trans-isomer of the Xaa-Pro motif in the MBD corresponds with the normal or abnormal form of tau, as seen for phosphorylated Thr231-Pro232, FKBP12 might be able to restore abnormal forms of tau protein to its normal forms. Thus, FKBP12 is a candidate to regulate tau protein by interacting with its MBD.
Here, we synthesized a peptide that corresponds to the R3 region of tau protein (R3 peptide) and investigated whether or not FKBP12 prevents its aggregation in vitro under various conditions by fluorescence and dynamic light scattering measurements. In the present study, we focused on the early stage of aggregation of the R3 peptide because Pin1 affected tau protein at the early stage of aggregation (Ramakrishnan et al., 2003; Nakamura et al., 2012) . The early stage of aggregation, however, is poorly understood, particularly because of the difficultly of its detection. Thus, we labeled the R3 peptide with fluorescein to increase sensitivity. First, we checked if fluorescein did not change the nature of the peptide with respect to aggregation and investigated the aggregation mechanism for the R3 peptide by measuring aggregation under various conditions. We then measured the aggregation of the R3 peptide in the presence of FKBP12 in order to investigate the aggregation inhibitory activity of FKBP12. As a result, higher the concentration of FKBP12 became, less the aggregation of the R3 peptides was detected. Next, we investigated the aggregation inhibitory mechanism by FKBP12 by introducing two types of mutations Val55 ! Arg and Tyr82 ! Lys. The former mutation increased the activity 11-fold, whereas the latter decreased it 7-fold. We globally analyzed the relationship between the PPIase activity of FKBP12 and the aggregation inhibitory activity. On the basis of these results, we concluded that the PPIase activity of FKBP12 prevented the R3 peptide from aggregating.
Materials and methods

Chemicals
Heparin sodium was of Wako Special Grade from Wako Pure Chemical Industries Ltd. All other chemicals were of guaranteed reagent grade.
Peptides and proteins
The R3 and R4 peptides, the sequences of which are shown in Fig. 1 , were chemically synthesized using a solid-phase peptide synthesizer (Sigma Aldrich Japan K.K.). A fluorescein and an amide group were attached to the N-terminal amide group of Val1 and the C-terminal carboxyl group of Glu31 in the R3 peptide, respectively. TAMRA and amide group were attached to the N-terminal amide group of Val1 and the C-terminal carboxyl group of Asn32 in the R4 peptide, respectively. Their purity was 94.4 and 98.7% for the R3 and R4 peptides, respectively, as determined by mass spectrometry. These peptides were obtained in lyophilized form.
Wild-type human FKBP12 and its two mutants, FKBP12/ Val55Arg and FKBP12/Tyr82Lys, were expressed and purified as described previously (Ikura and Ito, 2007) .
Time-dependent fluorescence measurement
Aggregation of the R3 peptide quenched the fluorescence of fluorescein attached to the peptide; as the peptide became more aggregated, the change in fluorescence intensity became larger, as shown in Fig. 2a . Therefore, time-dependent change in fluorescence intensity by fluorescein was measured by a JASCO FP-6500 spectrofluorometer to monitor the timecourse of aggregation of the R3 peptide. The excitation and emission wavelengths were 450 and 520 nm, respectively. Before measurements were taken, 1500 ml of each buffer solution including salt, heparin, reducing agent or FKBP12, was pre-incubated at 258C in a rectangular optical cell settled in a Peltier thermostatted cell holder with a magnetic stirrer. Aggregation of the R3 peptide was initiated by diluting 1.5 ml of 5 mM (or 15 ml of 0.5 mM) of the R3 peptide dissolved in 100% dimethyl sulfoxide (DMSO) in the optical cell. Fluorescence intensity was recorded with time intervals from 5 min to 4 -60 h after mixing the peptide. On the other hand, we measured time-dependent change in fluorescence intensity by TAMRA to monitor time-course of aggregation of the R4 peptide as a control experiment. The excitation and emission wavelengths were 500 and 575 nm, respectively. The other experimental conditions and procedures for the R4 peptide were the same as those for the R3 peptide.
Fluorescence depolarization measurements
The fluorescence depolarization of fluorescein attached to the R3 peptide was measured by the Peltier thermostatted depolarization accessory settled on JASCO FP-6500 spectrofluorometer to investigate the interaction between the R3 peptide and FKBP12 (Weber, 1953; Lakowicz, 1983) . The excitation and emission wavelengths were 450 and 520 nm, respectively. Before measurements, 1500 ml of each buffer solution including appropriate amount of FKBP12 was pre-incubated at 258C in a rectangular optical cell settled in the Peltier thermostatted cell holder with a magnetic stirrer. Then, 3 ml of 0.5 mM of the R3 peptide solved in 100% DMSO was diluted in the solution. The final concentration of the peptide was set to 1 mM, because aggregation of the peptide was not detected at this concentration. Fluorescence depolarization was measured at least 20 times for each condition, and then averaged. These measurements gave apparent dissociation constants (K d ) averaged for both of the cis-and trans-isomers. 
Dynamic light scattering measurement
Aggregation of the R3 and R4 peptides were directly monitored at 258C by dynamic light scattering method using Marvern Zetasizer mV. During aggregation measurement, we collected 4 ml of the reaction mixture at hourly intervals and measured ingredient size in the mixture by a laser beam of 830 nm at an angle of 908.
Numerical analysis
Numerical analyses were performed using the Mathematica 9.0 software package (Wolfram Res.).
Results
Characterization of the R3 peptide's aggregation
To characterize aggregation of the R3 region of tau protein, we chemically synthesized the R3 peptide, the N-terminal valine of which was labeled with fluorescein ( Fig. 1) , and investigated its aggregation under various conditions by change in the fluorescence intensity of fluorescein. Aggregation of tau protein and peptides has been conventionally monitored with thioflavin-S (ThS), which quantitatively associates with their aggregated forms. However, it was recently revealed that ThS itself increased the amount of aggregation of tau protein (Carlson et al., 2007; Perez et al., 2007) . Thus, we directly labeled the tau peptide with fluorescein to monitor its aggregation in order to exclude ThS-induced artifacts.
Inducer. Polyanionic compounds, such as heparin, are well known as in vitro inducers for aggregation of the R3 peptide, as well as the tau protein, although the physiological inducer for NFT is not known (Carlson et al., 2007) . Initially, we determined whether or not heparin had a similar effect on aggregation of the labeled R3 peptide, because no experimental data have been reported for the labeled R3 peptide (Fig. 2a) . As reported for the non-labeled peptides (Mizushima et al., 2006) , 5 mM of the labeled R3 peptide rapidly aggregated in the presence of 60 mg/ml of heparin, and then its aggregates gradually grew into larger particles. We also found that the peptide aggregated at this concentration even in the absence of heparin (Fig. 2a) . The aggregation in the absence of heparin, The aggregation of 5 mM of the R3 peptide at pH 8.0 in the presence of 10 mM TCEP, and in 0 (empty circle), 100 (empty square) or 400 (empty rhombus) mM sodium chloride. (f ) The aggregation of 5 mM of the R3 peptide in the presence of 10 mM TCEP, and at pH 4.5 (empty circle), 5.9 (empty square), 6.9 (empty rhombus), 8.0 (empty triangle) or 9.4 (multiplication sign). The aggregation of 5 mM of the R3 peptide at pH 8.0 in the presence of 10 mM TCEP was redundantly plotted in the panels (c), (d), (e) and (f) as a control data. The curve fitting was performed by applying a Stineman interpolating function to the data on KaleidaGraph (Hukinks).
however, grew much slower than that in the presence of heparin. The sizes of the aggregated particles were measured by the dynamic light scattering method; after 20 min, the aggregations grew into large particles with mean hydrodynamic radiuses of 206.8 + 130.6 and 16.30 + 8.97 nm in the presence and absence of heparin, respectively. These aggregations were still soluble in the aqueous solution at that time, but precipitated within 60 h. In contrast, the labeled R4 peptide did not aggregate under the same condition (Fig. 2b) , as reported by Mizushima et al. (2006) . These results indicate that the R3 peptide intrinsically has a high propensity to aggregate. Heparin was not necessary for the R3 peptide to aggregate, but it enhanced aggregation of the R3 peptide.
Saturation point. What is the minimum concentration (saturation point) for the R3 peptide to aggregate? In general, proteins have higher aggregation propensities at lower saturation points. Is this general property true for the R3 peptide? To answer this question, we investigated aggregation of the R3 peptide at three different concentrations, 1, 5 and 10 mM, to elucidate its concentration-dependence in aggregation, in the absence of any inducer. Figure 2c shows that 5 and 10 mM of the peptide formed aggregates, whereas 1 mM of the peptide did not. These results indicate that the saturation point of the R3 peptide is between 1 and 5 mM in the absence of heparin. This value is similar to the saturation point for the intact tau protein observed in the presence of heparin (Carlson et al., 2007) . This, however, seems quite high in contrast with the a-amyloid (1 -40) peptide, which aggregates at 40 nM under a specific condition (Ding et al., 2012) . Thus, the tau protein may be rather soluble among proteins forming amyloid-like fibers.
Oxidation. The tau protein isoforms have, at most, two cysteine residues. For example, the N2R4 isoform (441 amino acid residues) contains Cys291 and Cys322. Both cysteine residues are located in the MBD, Cys291 in the R2 region, and Cys322 in the R3 region. These cysteine residues formed intramolecular and intermolecular disulfide bonds and accelerated the aggregation of tau peptides (Sugino et al., 2009) . In the present study, only one cysteine residue, Cys322 (Cys17 in the R3 peptide's sequence), was included in the R3 peptide, suggesting that it was able to dimerize the peptide under oxidative conditions. Thus, we investigated how the oxidation of Cys17 affected the aggregation of the R3 peptide. Figure 2d shows that the R3 peptide aggregated much faster under the oxidative condition than under the reductive condition, suggesting that dimerization of the R3 peptide accelerates the aggregation. According to Sugino et al. (2009) , two types of tau peptides, 4RMDB (R1-R2 -R3-R4) and 3RMDB (R1 -R3-R4), formed homodimers, with an intramolecular and intermolecular disulfide bond, respectively. After dimerization, the peptides assemble into large aggregations, depending on their sequences. The R3 peptide also aggregated under the oxidative condition, and the aggregation rate was almost the same as that of the rate of 3RMDB. Thus, the mechanism of aggregation of the R3 peptide was expected to be the same as that of 3RMDB, although they did not specifically mention it (Sugino et al., 2009) . The disulfide bonds, however, were not essential for the aggregation of tau peptides, including R3, 3RMDB and 4RMBD. These tau peptides aggregated, even under the reductive condition (Fig. 2d) (Sugino et al., 2009) , suggesting that the aggregation mechanism under the reductive condition was different from the mechanism under the oxidative condition.
Salt effect. As shown above, heparin accelerated aggregation of the R3 peptide (Fig. 2a) , suggesting that the aggregation of the peptide was driven mainly by hydrophilic interactions. Here, we measured the aggregation of the R3 peptide under various salt concentrations in the presence of the reductant to elucidate the charge effect on the aggregation. Figure 2e shows that the aggregation of the R3 peptide decreased when the salt concentration increased. The R3 peptide did not aggregate in the presence of 400 mM of sodium chloride. This result also indicated that the hydrophilic interactions affect the aggregation of the R3 peptide considerably. pH dependency. We next investigated the type of hydrophilic amino acid residues responsible for aggregation of the R3 peptide. The R3 peptide includes eight hydrophilic residues, one aspartic acid residue, two histidine residues, four lysine residues and one tyrosine residue. Thus, we measured the aggregation of the R3 peptide at five different pHs, 4.5, 5.9, 6.9, 8.0 and 9.4, in the presence of reductant. The electrostatic interaction of the R3 peptide almost vanished at pH 9.4, because the isoelectric point of the R3 peptide is theoretically 9.98. This suggests that the hydrophobic effects were greatest at pH 9.4. In contrast, lower the pH becomes, more positive the net charge of the R3 peptide becomes. This suggests that the hydrophilic effects become the largest at pH 5.9. At the mid-range pHs, both the hydrophilic and hydrophobic effects were medium, but distribution of the local charge of the R3 peptide was dependent on the pH. We found that aggregation of the R3 peptide was at the minimum and maximum levels at pH 6.9 and 8.0, respectively (Fig. 2f ) , suggesting that the distribution of the local charge was more important for aggregation of the R3 peptide than the net charge of the peptide. Furthermore, the transition to aggregation of the R3 peptide occurred between pH 6.9 and 8.0, suggesting that distribution of the local charge of the peptide changed between pH 6.9 and 8.0. One of the candidate mechanisms for changing the charge is deprotonation of the histidine residue. The R3 peptide contains two histidine residues, His24 and His25. The local positive charge around the histidine residues might be related to aggregation of the R3 peptide.
In summary, the R3 peptide aggregated even in the absence of inducer, and the aggregation was driven by hydrophilic interaction. The deprotonation of histidine seemed to affect aggregation of the peptide.
Aggregation inhibition by FKBP12
The R3 peptide contains two proline residues, Pro7 and Pro27. The proline residues are not the target for Pin1 but are the targets for FKBP12, because Lys6 and Lys26 precede the proline residues (Yaffe, 1997) . In order to elucidate the aggregation inhibitory activity of FKBP12, we measured aggregation of the R3 peptide in various concentrations of FKBP12 by change of fluorescence intensity of fluorescein. Figure 3a shows that R3 peptide aggregation decreased when the concentration of FKBP12 increased. No peptide aggregation was detected in the presence of 20 mM of FKBP12. This result clearly indicated that FKBP12 prevents the R3 peptide from aggregating. We calculated that 50% inhibitory concentration (IC 50 ) of FKBP12 under the conditions was 3 mM (Fig. 3b) .
There are two possible explanations for the mechanism of how FKBP12 prevents the R3 peptide from aggregating (Schemes 1 and 2). One is that FKBP12 sequesters the R3 peptide: (i) FKBP12 tightly binds to the R3 peptide, (ii) the effective concentration of the R3 peptide decreases to less than its saturation point and (iii) FKBP12 also interacts with oligomers of the R3 peptide at the early stage of aggregation, leading to dissociation of the peptide (Scheme 1). The other possible explanation is that FKBP12 catalyzes isomerization from the higher aggregation-prone isomer to the lower one: (i) FKBP12 binds more tightly to the higher aggregation-prone isomer of the R3 peptide than to the lower one, and (ii) FKBP12 catalyzes isomerization from the higher aggregationprone isomer to the lower one as well as Pin1 and (iii) FKBP12 also functions for oligomers of the R3 peptide at the early stage of aggregation, leading to dissociation of the peptide (Scheme 2). Both schemes have the association of FKBP12 with the R3 peptide in common. However, they are Scheme 1. The inhibitory mechanism of R3 peptide aggregation by simple binding of FKBP12. In this scheme, only the cis-isomer of the R3 peptide can aggregate, to which FKBP12 specifically and tightly binds. FKBP12 catalyzes isomerization of Xaa-Pro motifs of the R3 peptide only in the monomeric state. Association between FKBP12 and the cis-isomer is much faster than self-association of the cis-isomer because the concentration of the cis-isomer is very low. Therefore, FKBP12 intercepts the cis-isomer during its aggregation.
Scheme 2. The inhibitory mechanism of R3 peptide aggregation by PPIase activity of FKBP12. In this scheme, only the cis-isomer of the R3 peptide can aggregate, and FKBP12 does not tightly bind to either isomer. FKBP12 catalyzes isomerization of Xaa-Pro motifs of the R3 peptide in both the monomeric and aggregative state. Once the cis-isomer is converted into the trans-isomer in the aggregative state, the trans-isomer is quickly released from the aggregation because the trans-isomer cannot aggregate. different in the catalytic reaction of FKBP12. FKBP12 only sequesters the peptide in the former scheme, while it catalyzes the isomerization of Xaa-Pro bonds of the peptide in the latter scheme.
To determine which scheme is applicable to the function of FKBP12, we introduced two types of mutations into FKBP12; one mutation increased the PPIase activity, and the other mutation decreased the activity. A Val55 ! Arg mutation (FKBP12/Val55Arg) increased PPIase activity by a factor of 11, while a Tyr82 ! Lys mutation (FKBP12/Tyr82Lys) decreased the activity by a factor of 7 (Fig. 4a) (Ikura and Ito, 2007) . In order to elucidate the effect of PPIase activity, we measured the aggregation of 5 mM of the R3 peptide in the presence of 5 mM of each of these mutant proteins by change in fluorescence intensity of fluorescein. Moreover, in order to elucidate how the mutations affect the association between FKBP12 and the R3 peptide, we measured the affinities of the proteins to the R3 peptide by the fluorescence depolarization method. In this affinity study, concentration of the R3 peptide was decreased to 1 mM because the R3 peptide did not aggregate at this concentration (Fig. 2c) . As the results indicated, the R3 peptide did not aggregate in the presence of FKBP12/ Val55Arg, while FKBP12/Tyr82Lys did not inhibit the aggregation (Fig. 4b) . In the presence of FKBP12/Val55Arg, the R3 peptide aggregated transiently at first, then gradually dissociated and finally, the peptide was completely restored from the aggregation. The apparent dissociation constant (K d ) for wild-type FKBP12 was calculated as 271 mM, whereas the K d s for each of the two mutants was much .271 mM (Fig. 4c) . These affinities were too low for K d calculation by the fluorescence depolarization method. These results indicated that higher the PPIase activity of FKBP12, higher its aggregation inhibitory activity. The results also indicated that the aggregation inhibitory activity of FKBP12 was independent of the affinity between FKBP12 and the R3 peptide. Therefore, the aggregation inhibitory activity of FKBP12 depended only on the PPIase activity of FKBP12, as represented by Scheme 2.
Discussions
Mechanism of FKBP12 inhibition of R3 peptide aggregation
As shown in Fig. 3a , 20 mM of FKBP12 completely inhibited aggregation of the R3 peptide. Mutational studies on FKBP12 showed that the aggregation inhibitory activity of FKBP12 is attributable mainly to its PPIase activity (Fig. 4b and c) . Furthermore, FKBP12 not only acted on the R3 peptide in the monomeric state but also in the aggregative state (Fig. 4a) . This restoration of the R3 peptide from aggregate to monomer suggests that the R3 peptide aggregation formed at the early stage does not strongly resist the attack by FKBP12. These features of the aggregation of the R3 peptide in the presence of FKBP12 are well described in Scheme 2. On the other hand, the mutational studies showed that the aggregation inhibitory mechanism of FKBP12 was inconsistent with Scheme 1, because the mutation Val55 ! Arg weakened the association between FKBP12 and the peptide, but raised the aggregation inhibitory activity (Fig. 4b and c) . Here, we theoretically examined how Scheme 2 reproduced the experimental results. In simulating the inhibition of R3 peptide aggregation by FKBP12 in Scheme 2, we simplified the reaction so that (i) only the cis-isomer of the Xaa-Pro motif aggregated irreversibly, (ii) FKBP12 accelerated the isomerization between cisand trans-isomers in monomeric and aggregative states and (iii) only the trans-isomer in the aggregative state quickly dissociated from the aggregation. As a result, the acceleration of isomerization decreased the amount of aggregation of the R3 peptide (Fig. 5) , indicating that Scheme 2 describes the experimental results, in which FKBP12 restored the R3 peptide from the aggregation. Although no structural information is available to explain the difference between the cis-and trans-isomers, we can interpret this issue on the basis of pH dependency of the aggregation (Fig. 2f ) . Aggregation of the R3 peptide was sensitive to the distribution of local charge. The cis-and trans-isomers are probably different from each other in the distribution of local charge. Therefore, the cis-isomer is much aggregative than the trans-isomer, as reported for the aggregation propensity of the pThr231-Pro232 motif (Nakamura et al., 2012) .
In 2001, von Bergen et al. pointed out that Pro312 was important for aggregation propensity of the R3 peptide (von Bergen et al., 2001) . They reported that a deletion mutant of a short R3 peptide (Val306-Lys317), which lacked only Pro312, showed a pronounced shift to b-structure and enhanced the aggregation, indicating that the aggregation propensity of the R3 peptide correlated with the b-structure content for residues around the Val306-Lys311 motif, and Pro312 in the intact sequence broke elongation of b-structure by its restricted conformation. This means that Pro312 suppresses aggregation of the R3 peptide. Although they did not investigate the isomerization of Pro312, this suppressive effect should be brought about by the trans-isomer because it is in majority. The cis-isomer might have higher b-structure content for the R3 peptide than the trans-isomer. Therefore, isomerization of Pro312 presumably attributes to the aggregation propensity of the R3 peptide.
In vivo function of FKBP12
FKBP12 was first discovered as the receptor for an immunosuppressor in the immune system (Harding et al., 1989; Siekierka et al., 1989) . It was later revealed that FKBP12 had multiple functions in cells. FKBP12 interacts with signal transduction proteins such as the type-1 transforming growth factor receptor (Chen et al., 1997) , and with multiple intracellular calcium release channels, such as the tetrameric skeletal muscle ryanodine receptor (Gaburjakova et al., 2001) . FKBP12 is also abundantly expressed in the brain and accumulates in NFT (Sugata et al., 2009 ). However, whether or not FKBP12 is concerned with the aggregation process of tau protein was still unclear. In this study, we clearly demonstrated that FKBP12 prevented the R3 peptide from aggregating in vitro. Although a short fragment of tau protein, the R3 region was essential for tau protein to aggregate (Perez et al., 2007) . Therefore, it is expected that FKBP12 prevents tau protein aggregation by interacting with the R3 region of tau protein in vivo, as it acts upon the R3 peptide in vitro. In its in vitro aggregation inhibitory activity, FKBP12 catalyzed the isomerization both of monomeric and aggregative states, suggesting that such isomerization catalysis is also essential for its in vivo aggregation inhibitory activity.
PPIase versus NFT
At least four PPIases, Pin1, FKBP12, FKBP51 and FKBP52, are estimated to be responsible for stabilizing and destabilizing the tau protein in vivo (Cao and Konsolaki, 2011; Nakamura et al., 2012) . Pin1 interacts with the pSer/Thr-Pro motifs in the tau protein and isomerizes the higher aggregative cis-isomer to the low aggregative trans-isomer. The functions of FKBP51 and FKBP52 are related to association and dissociation between the tau protein and two types of tubulins. However, whether or not the PPIase activities of both FKBPs are concerned with the function is unknown, because they consist of several functional domains. On the other hand, this study suggested that PPIase activity of FKBP12 was essential in preventing tau protein aggregation. Thus, many PPIases and their PPIase activities regulate the tau protein. Such a feature of the tau protein might be related to one of its structural properties, in which it is intrinsically disordered (Skrabana et al., 2006) .
